The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESC 2026 | Managing patients flagged as high risk for ATTR-CM: insights into the multidisciplinary approach
Ilia Davarashvili, MD, Leumit Health Services and Leumit Start, Tel Aviv, Israel, comments on the multidisciplinary approach once an AI algorithm flags someone as high risk for cardiac transthyretin amyloidosis (ATTR-CM). Dr Davarashvili highlights that community cardiologists play a crucial role in the initial stages of diagnosis, and once a diagnosis is confirmed, patients can be transferred to specialized teams for further management. This interview took place during the 2026 European Society of Cardiology (ESC) Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Really ATTR-CM is a multidisciplinary field involving general practitioner, community cardiologists as we suppose should be, heart failure amyloidosis specialists and the hematologists as well. So there is no specific ownership. The question is who is the first one and who goes afterwards with the pathway and who are the game players afterwards but I think the algorithm should put an alert and an emphasis on the community cardiologist who should just be aware of the alert flagged patient to take him to the right pathway screening, maybe performing an updated echocardiographic imaging, to rule out AL amyloidosis as well, knowing that it’s very important to rule out promptly or to start the treatment for the hematologist team...
Really ATTR-CM is a multidisciplinary field involving general practitioner, community cardiologists as we suppose should be, heart failure amyloidosis specialists and the hematologists as well. So there is no specific ownership. The question is who is the first one and who goes afterwards with the pathway and who are the game players afterwards but I think the algorithm should put an alert and an emphasis on the community cardiologist who should just be aware of the alert flagged patient to take him to the right pathway screening, maybe performing an updated echocardiographic imaging, to rule out AL amyloidosis as well, knowing that it’s very important to rule out promptly or to start the treatment for the hematologist team. And afterwards, after confirming the diagnosis, the patient can be transferred to the heart failure team, to the amyloidosis team. So this should be the pathway. But it doesn’t say that the community cardiologist should be afraid of studying the amyloidosis specialist, but he should know who is the owner of the prompt efficacy pathway.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
